A Phase 3, Randomized, Open-Label, Multicenter Study Comparing the Efficacy and Safety of the Bruton’s Tyrosine Kinase (BTK) Inhibitors BGB-3111 and Ibrutinib in Subjects with Waldenström’s Macroglobulinemia (WM)

Project: Research

Project Details

StatusActive
Effective start/end date5/12/19 → 4/12/24

Keywords

  • clinical trial
  • phase 3 study
  • treatment efficacy
  • treatment safety
  • Lymphoma